Harlan Waksal Net Worth

The estimated Net Worth of Harlan Waksal is at least $7.23 Milion dollars as of 10 November 2023. Harlan Waksal owns over 25,000 units of Kadmon Inc stock worth over $2,488,677 and over the last 8 years he sold KDMN stock worth over $0. In addition, he makes $4,742,770 as President, Chief Executive Officer a Director at Kadmon Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Harlan Waksal KDMN stock SEC Form 4 insiders trading

Harlan has made over 10 trades of the Kadmon Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of KDMN stock worth $74,000 on 10 November 2023.

The largest trade he's ever made was buying 236,966 units of Kadmon Inc stock on 12 April 2022 worth over $999,997. On average, Harlan trades about 12,291 units every 102 days since 2016. As of 10 November 2023 he still owns at least 261,966 units of Kadmon Inc stock.

You can see the complete history of Harlan Waksal stock trades at the bottom of the page.

Harlan Waksal biography

Dr. Harlan W. Waksal M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Waksal has been our President and Chief Executive Officer since August 2014 and was elected to our Board in 2013. Prior to joining Kadmon as an employee, Dr. Waksal served as President and Sole Proprietor of Waksal Consulting LLC from 2003 to 2014. From 2011 to 2014, Dr. Waksal served as Executive Vice President, Business and Scientific Affairs at Acasti Pharma, Inc., a publicly traded biopharmaceutical company, and as a consultant to Neptune Technologies & Bioressources, Inc., a publicly traded life sciences company and the parent company of Acasti. Dr. Waksal co-founded ImClone Systems (“ImClone”) in 1987, a publicly traded biopharmaceutical company acquired by Eli Lilly and Company in 2008. Dr. Waksal served in senior roles at ImClone, including: President (1987 to 1994); Executive Vice President and Chief Operating Officer (1994 to 2002); and President, Chief Executive Officer and Chief Operating Officer (2002 to 2003). Dr. Waksal also served as a Director of ImClone from 1987 to 2005. Dr. Waksal served on the boards of Oberlin College and Sevion Therapeutics through March 2016 and the boards of Acasti and Neptune through February 2016 and July 2015, respectively. Dr. Waksal received his B.A. from Oberlin College and his M.D. from Tufts University School of Medicine. He completed his training in internal medicine at New England Medical Center and in pathology at Kings County Hospital Center in Brooklyn.

What is the salary of Harlan Waksal?

As the President, Chief Executive Officer a Director of Kadmon Inc, the total compensation of Harlan Waksal at Kadmon Inc is $4,742,770. There are no executives at Kadmon Inc getting paid more.

What's Harlan Waksal's mailing address?

Harlan's mailing address filed with the SEC is C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN, MA, 02472.

Insiders trading at Kadmon Inc

Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ... a Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.

What does Kadmon Inc do?

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Complete history of Harlan Waksal stock trades at Kadmon Inc a Lyra Therapeutics

Kadmon Inc executives and stock owners

Kadmon Inc executives and other stock owners filed with the SEC include:

• Harlan Waksal,
  President, Chief Executive Officer, Director
• Steven Meehan,
  Chief Financial Officer, Executive Vice President
• Gregory Moss,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Dr. Harlan W. Waksal,
  Pres, CEO & Director
• Gregory S. Moss Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Arthur Kirsch,
  Independent Director
• David Cohen,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Eugene Bauer,
  Independent Director
• Tasos Konidaris,
  Non-Executive Independent Chairman of the Board
• Ellen Cavaleri,
  IR Contact Officer
• Nancy Miller-Rich,
  Director
• John Ryan,
  Executive Vice President, Chief Medical Officer
• Dr. Simon Cooper,
  Sr. VP & Chief Medical Officer
• Haya Taitel M.S., R.Ph.,
  Sr. VP & Chief Commercial Officer
• Sanjay Aggarwal,
  Sr. VP of Clinical Devel.
• Kyle Carver,
  Sr. VP, Chief Accounting Officer & Controller
• Charles Darder,
  Principle Accounting Officer
• Asset Management Lp Golden ...,
  
• D. Dixon Boardman,
  
• Konstantin Poukalov,
  EVP, Chief Financial Officer
• Alexandria Forbes,
  
• Andrew B Cohen,
  
• I, Llc Kadmon,
  
• Susan Wiviott,
  
• Shengda Zan,
  
• Thomas E Shenk,
  
• Steven N. Gordon,
  Exec VP, GC, Chief Admin, Comp
• Lawrence Kenneth Cohen,
  Exec. VP, Business Develop.
• Daniel S Third Point Llc Loeb,
  
• Bart M Schwartz,
  
• Advisors Llcperceptive Life...,
  
• Kyle Carver,
  SVP, CAO, Controller
• Cynthia Louise Flowers,
  Director